Farxiga (dapagliflozin) is superior to Januvia (sitagliptin) for kidney disease
For patients with chronic kidney disease, Farxiga (dapagliflozin) should be the preferred choice over Januvia (sitagliptin) based on proven renal protection, reduction in kidney failure, and mortality benefits that sitagliptin does not provide.
Why Farxiga is the Clear Winner
Strong Guideline Support for SGLT-2 Inhibitors
The most recent 2024 BMJ guidelines provide a strong recommendation for SGLT-2 inhibitors (including dapagliflozin/Farxiga) in patients at very high risk of CKD progression, and suggest their use even in low-risk CKD patients 1. The 2022 ADA/KDIGO consensus explicitly recommends "an SGLT2i with proven kidney or cardiovascular benefit" for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 2.
Notably, DPP-4 inhibitors like Januvia are not mentioned in any guideline as having renal protective benefits - they are only discussed for dose adjustments based on kidney function 2.
Proven Renal Outcomes with Farxiga
The landmark DAPA-CKD trial demonstrated that dapagliflozin:
- Reduced kidney failure risk by 58 per 1000 patients (high certainty evidence) 1
- Decreased all-cause mortality by 48 per 1000 patients in very high-risk CKD 1
- Reduced the composite renal outcome by 39% (hazard ratio 0.61) including sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death 3
- Slowed eGFR decline by approximately 1 mL/min/1.73 m² per year compared to placebo 4
These benefits occurred regardless of diabetes status - the drug works in CKD patients with or without type 2 diabetes 3, 5.
Sitagliptin Has No Proven Renal Protection
While one recent real-world study compared empagliflozin (another SGLT-2 inhibitor) to sitagliptin and found slower eGFR decline with the SGLT-2 inhibitor 6, there are no randomized controlled trials demonstrating that sitagliptin prevents kidney failure, slows CKD progression, or reduces mortality. A 2026 network meta-analysis confirmed that DPP-4 inhibitors conferred no renal benefit 7.
Sitagliptin's role in CKD is limited to glycemic control with dose adjustments: 50 mg daily for eGFR 30-44 mL/min/1.73 m², and 25 mg daily for eGFR 15-29 mL/min/1.73 m² 2.
Practical Implementation
When to Use Farxiga
- Initiate at 10 mg daily for patients with CKD and eGFR ≥25 mL/min/1.73 m² 8
- Can be started down to eGFR ≥20 mL/min/1.73 m² based on recent evidence 2
- Continue even if eGFR falls below initiation threshold - trials showed patients could safely continue therapy as kidney function declined 2
- Works across all albuminuria levels, including patients without significant proteinuria 9
Expected Effects
- Acute eGFR dip of 2-3 mL/min/1.73 m² in first 2 weeks - this is hemodynamic, reversible, and does not indicate harm 4
- After initial dip, expect stabilization or slowing of eGFR decline 4, 9
- Benefits extend beyond kidneys: reduced heart failure hospitalization and cardiovascular death 3, 5
Key Monitoring and Safety
- Monitor for volume depletion - consider reducing diuretics in high-risk patients 2
- Watch for genital mycotic infections (6% vs 1% placebo) - counsel on hygiene 2
- In insulin-requiring patients, maintain at least low-dose insulin and hold during acute illness to prevent euglycemic ketoacidosis 2
- No dose adjustment needed as eGFR declines once initiated 8
The Bottom Line
Farxiga provides proven kidney protection with high-certainty evidence for preventing kidney failure and death, while Januvia offers only glycemic control without demonstrated renal benefits. The choice is clear: unless there are specific contraindications to SGLT-2 inhibitors (such as recurrent genital infections or intolerance), Farxiga should be the preferred agent for patients with chronic kidney disease 1, 2, 3, 7.